Children's Hospital Medical Center, Cincinnati

571 total trials 106 currently recruiting 372 completed

Children's Hospital Medical Center, Cincinnati sponsors 571 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 372 completed. 38 of these trials are in Phase 3-4 (later-stage) and 140 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 13 trials.

Trial Pipeline

571 total, page 5 of 12

COMPLETED Phase 1

Hp129 Xenon Imaging and BOS in Lung Transplantation

NCT03603899

COMPLETED Phase 1

Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants

NCT04595513

COMPLETED Phase 1

Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients

NCT04263597

TERMINATED

Serology to COVID-19 for Recording Exposures and Evaluating Needs

NCT04566965

COMPLETED NA

Diabetes Journey: An Adolescent Adherence Barriers Intervention

NCT04404556

COMPLETED NA

Teaching Healthy Responsive Parenting During Infancy to Promote Vital Growth and dEvelopment (THRIVE) Study

NCT04989738

COMPLETED NA

Adolescent Sexually Transmitted Infection Screening in the Emergency Department

NCT03715335

COMPLETED NA

Virtual Reality for Appendectomy Pain

NCT04357132

COMPLETED NA

Virtual Reality and Pain

NCT04351776

COMPLETED NA

Parent Emotion Coaching for Anorexia Nervosa

NCT04421989

COMPLETED

Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA

NCT04413955

COMPLETED NA

Web Based Tools to Improve Medication Continuity in Adolescents With ADHD

NCT04386096

COMPLETED NA

Time Restricted Nutrition in Pediatric Stem Cell Transplant Recipients

NCT04549038

COMPLETED

Repeated Employee Testing for Understanding Our Recovery to Normal

NCT04472793

COMPLETED NA

Preschool ADHD On-line Behavioral Treatment

NCT04402528

COMPLETED NA

Trial of a Decision Support Intervention for Adolescents and Young Adults With Ulcerative Colitis

NCT04207008

COMPLETED Phase 2

Nitrate Effect on Exercise Capacitance

NCT04297241

COMPLETED NA

Using Technology-Assisted Stepped Care Intervention to Improve Adherence in Adolescents With Asthma

NCT04365556

COMPLETED

Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)

NCT04131504

COMPLETED NA

Tacrolimus Microsampling

NCT04810143

TERMINATED Phase 2

Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients

NCT04117477

TERMINATED Phase 2

TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders

NCT04088760

COMPLETED NA

Behavioral Economics and Adherence in Teens (BEAT!)

NCT03958331

COMPLETED NA

Human-Animal Interaction to Promote Recovery Following Pediatric Brain Injury

NCT04016961

COMPLETED NA

Tools to Improve Medication Continuity in Adolescents With ADHD

NCT04173000

COMPLETED NA

Impact of a Breath-controlled Video Game App

NCT04000646

COMPLETED Phase 1

Cysteamine for Asthma

NCT03883984

COMPLETED NA

Web-Based Self-Monitoring Activity-Restriction and Relaxation Training Program for Kids With Mild Traumatic Brain Injury

NCT03498495

COMPLETED NA

Response Inhibition in Tourette Syndrome

NCT03628703

COMPLETED Phase 1

A Proof-of-Concept Study of Minocycline in Autism

NCT04031755

COMPLETED NA

Epilepsy Adherence in Children and Technology (eACT)

NCT03817229

COMPLETED NA

Randomized Trial of LENA Home in A Home Visiting Program

NCT04031326

COMPLETED Phase 2

Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

NCT03883906

COMPLETED NA

Comparing Children's Books to Brochures for Safe Sleep and Infant Reading Education During Prenatal Care

NCT04031235

COMPLETED Phase 2

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

NCT04481035

COMPLETED

LDL-Apheresis for FSGS CardioRenal Outcomes

NCT04088799

COMPLETED

Early MRI Prediction of Crohns

NCT03340519

COMPLETED NA

Sleep After Adolescent Concussion

NCT03781076

COMPLETED NA

Technology-Assisted Stepped Care Study

NCT03883594

COMPLETED NA

Hearing Aid Noise Reduction in Pediatric Users (Oticon Study)

NCT03771287

COMPLETED NA

Validation of Low Dose CT for Diagnosis of Lung Nodules

NCT03681873

TERMINATED NA

Validation of Low Dose CT for Diagnosis of Urolithiasis

NCT03656913

COMPLETED

Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene

NCT03892798

COMPLETED Phase 3

Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

NCT03568708

COMPLETED NA

Treating Sleep in Teens With ADHD

NCT04270812

COMPLETED NA

Sensory Stimulation During Simulated Driving

NCT03726840

COMPLETED Phase 2

Mind and Body Approaches to Pain Reduction in Youth With Migraine

NCT03472092

COMPLETED NA

Daily Living Skills Intervention for 9th and 10th Graders With Autism Spectrum Disorders

NCT03984513

COMPLETED NA

Improving ADHD Behavioral Care

NCT03628781

COMPLETED NA

Enhanced Support for Behavioral Barriers to Learning: An Evaluation of the SCHOOL STARS Program

NCT03669289

← Previous Page 5 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 86
Phase 2 54
Phase 3 15
Phase 4 23

What the Pipeline for Children's Hospital Medical Center, Cincinnati Shows

According to the ClinicalTrials.gov registry, Children's Hospital Medical Center, Cincinnati is linked to 571 US clinical trials across every stage of research activity. Of those, 106 studies are currently recruiting, about 19% of the sponsor's indexed portfolio, and 372 are already marked complete, representing roughly 65% of the total.

The phase mix for Children's Hospital Medical Center, Cincinnati reports 38 late-stage studies (Phase 3 and Phase 4 combined) and 140 earlier-phase studies (Phase 1 and Phase 2).

The top therapeutic focus area indexed for Children's Hospital Medical Center, Cincinnati is Autism Spectrum Disorder with 13 linked trials, and 9 other condition areas appear in the top list above.

How to read these pipeline numbers

Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.